Indian Army and Air Force Conduct Joint Exercise in Arunachal Pradesh

Cognition Therapeutics has completed enrollment in its Phase 2 study of zervimesine (CT1812) in early Alzheimer's disease, with 540 participants targeted. The study will assess the safety and activity of the drug in participants with mild cognitive impairment or early Alzheimer's disease. Topline results are expected after 18 months of treatment. The company believes zervimesine has the potential to be an important treatment option for patients with Alzheimer's disease.